Precision medicine: Are we getting closer to N of 1? has been added to Bookmarks.
Precision medicine: Are we getting closer to N of 1?
Life Sciences & Health Care
April 14 | 1 p.m. ET
Cell, gene, and other emerging therapies are distinctly different from traditional biopharma products. Despite clinical and commercial promise, as with any new and innovative disruptive technology, cell and gene therapy stakeholders face challenges across the product life cycle. We'll discuss:
- The current state of next-generation therapy innovation in the life sciences and health care industry.
- Challenges and opportunities along key stages of the cell and gene value chain.
- Strategies and operating models needed to support broader adoption and potentially greater efficiency of delivering services in the future of health.
Participants will gain insights on emerging precision medicines and examine various approaches to bringing them to market.
Life Sciences & Health Care Dbriefs webcastView-On demand